Nordic Life Science
The latest business news
We would like to thank our readers, subscribers and collaboration partners for a fruitful, eventful and fun Q1 + Q2 2018, and we wish you all a most wonderful summer!
Oncopeptides present updated interim data from the ongoing HORIZON trial with Ygalo at the 23rd Congress of The European Hematology Association (EHA). The updated phase II-data show a clinical data
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
Nordic Life Science
The latest clinical trials
Phase II efficacy and safety data in patients with Mycosis Fungoides (MF) type early-stage Cutaneous T-cell Lymphoma (CTCL) demonstrated that remetinostat gel 1%, when applied topically twice daily, reduced the
The company has presented one-year data on survival rate, immune activation and safety in the modified cohort of the TG01 trial in resected pancreatic cancer patients. The trial is an
On 10-11 October the 4th annual event Outsourcing in Clinical Trials Nordics will be returning to the capital of Denmark. The 2 day event last September saw over 150 delegates
MedImmune, AstraZeneca’s global biologics R&D arm, have been informed by partner Celgene that the US Food and Drug Administration (FDA) has placed a partial clinical hold on five trials and a
Last Friday, Symphogen presents results from a randomized Phase 2 study with Sym004, a mAb mixture targeting EGFR. Their report ad results has been selected for oral presentation on 11
Medivir announces that the first patient has been enrolled in the company’s phase I/II study of birinapant in combination with the anti-PD-1 therapy KEYTRUDA (pembrolizumab), which is marketed by MSD.
Moberg Pharma reports positive clinical data for Kerasal Nail/ Emtrix showing that it produces a visible improvement after just one week for nails affected by onychomycosis and/or nail psoriasis. The early
Braeburn Pharmaceuticals and Camurus has announced positive results from a Phase 2 pharmacokinetic study of weekly and monthly buprenorphine (CAM2038) depots in opioid dependent patients with moderate-to-severe non-cancer chronic pain.
The Phase III FLAURA trial showed a statistically-significant and clinically-meaningful progression-free survival (PFS) benefit with Tagrisso (osimertinib) compared to current 1st-line standard-of-care treatment (erlotinib or gefitinib) in previously-untreated patients with locally-advanced or
The latest research findings from the Nordic region
Researchers at Karolinska Institutet have obtained the first 3D snapshots of a sperm protein attached to a complementary egg coat protein at the beginning of fertilisation. The study, which reveals
H. Lundbeck has entered into an agreement with biotech company ImmunoBrain Checkpoint for the rights to IBC’s groundbreaking research in the treatment of Alzheimer’s disease. The research focuses on modifying
Scientists at Karolinska Institutet report that cancer cells and normal cells use different ‘gene switches’ in order to regulate the expression of genes that control growth. In mice, the removal
Dr. Jan Holmgren has received the 24th annual Albert B. Sabin Gold Medal Award in honor of his pioneering work in mucosal immunology and leadership in the development the world’s first
In a new study presented in Molecular Psychiatry , researchers at Karolinska Institutet have measured how deposits of the pathological protein tau spread through the brain over the course of
The first analysis of how proteins are arranged in a cell was published yesterday in Science, revealing that a large portion of human proteins can be found in more than